Financial Results, Reports & Presentations
Menu
Annual Report 2019
In 2019, ViroGates achieved many significant milestones, including four new clinical routine customers, a pipeline of +50 hospitals evaluating the implementation of suPAR in clinical routine practice, and validation on all commercially relevant Roche Diagnostics cobas instruments. All these achievements are a result of the company’s core focus on commercializing its suPARnostic® products following the initial public offering in June 2018.
Financial Results Q1, 2020
Previous Interim Reports
Analyst Reports
2020
30 March 2020: Market Focus Update by Västra Hamnen Corporate Finance
29 January 2020: Market Focus Initial Research by Västra Hamnen Corporate Finance
2019
12 April 2019: Analyse af ViroGates A/S by Aktieinfo
2018
4 October 2018: Analyse af ViroGates A/S by Aktieinfo
Investor Presentations
2020
17 June 2020:
ABGSC Conference Call with ViroGates in “Weekly Window of Opportunity”, at 14.00-14.30 CET.
CEO Jakob Knudsen will present ViroGates business and visions.